Lexicon Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 1995-01-01
- Employees
- 285
- Market Cap
- $621.7M
- Website
- http://www.lexpharma.com
- Introduction
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company...
A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT03302845
- Locations
- πΊπΈ
Covance Clinical Research Unit, Dallas, Texas, United States
Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT03292653
- Locations
- πΊπΈ
Investigational Site Number 8400005, La Jolla, California, United States
π¨π¦Investigational Site Number 1240001, Toronto, Canada
π³π±Investigational Site Number 5280001, Groningen, Netherlands
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
- Conditions
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 571
- Registration Number
- NCT03285594
- Locations
- πΊπΈ
Investigational Site Number 8406003, New Port Richey, Florida, United States
πΊπΈInvestigational Site Number 8406052, Ocoee, Florida, United States
πΊπΈInvestigational Site Number 8406043, Coral Gables, Florida, United States
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
- Conditions
- Interventions
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 787
- Registration Number
- NCT03242252
- Locations
- πΊπΈ
Investigational Site Number 8404016, Savannah, Georgia, United States
πΊπΈInvestigational Site Number 8404057, Round Rock, Texas, United States
πΊπΈInvestigational Site Number 8404055, Houston, Texas, United States
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
- Conditions
- Interventions
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 277
- Registration Number
- NCT03242018
- Locations
- πΊπΈ
Investigational Site Number 8405018, San Dimas, California, United States
πΊπΈInvestigational Site Number 8405021, Clearwater, Florida, United States
πΊπΈInvestigational Site Number 8405036, Dallas, Texas, United States
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
- Conditions
- Interventions
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 507
- Registration Number
- NCT03066830
- Locations
- πͺπͺ
Investigational Site Number 2333003, Parnu, Estonia
π§π¬Investigational Site Number 1003002, Ruse, Bulgaria
πΊπ¦Investigational Site Number 8043002, Kyiv, Ukraine
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 399
- Registration Number
- NCT02926937
- Locations
- π²π½
Investigational Site Number 4841010, Aguascalientes, Mexico
π²π½Investigational Site Number 4841001, Culiacan, Mexico
π²π½Investigational Site Number 4841005, Durango, Durango, Mexico
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
- Conditions
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 518
- Registration Number
- NCT02926950
- Locations
- πΊπΈ
Investigational Site Number 8402041, Los Angeles, California, United States
πΊπΈInvestigational Site Number 8402006, Hialeah, Florida, United States
πΊπΈInvestigational Site Number 8402044, Hialeah, Florida, United States
Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT02647918
- Locations
- πΊπΈ
Lexicon Investigational Site, Saint Paul, Minnesota, United States
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
- Conditions
- Interventions
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 1405
- Registration Number
- NCT02531035
- Locations
- π¬π§
Lexicon Investigational Site, Northampton, United Kingdom